today. And everyone. for I and product Chief I've Inc. commercializes Thank XXXX. By future I launch I'm of conditions. introduction, way the Biofrontera's you, speaking since Biofrontera. the Monaco of products been And here treatment am Hermann. Operating Prior IPO was company Chief in to you to of pharmaceutical Officer. and excited our the our pleased good U.S. Executive skin Officer. be with dermatological afternoon, devices Financial for with Erica the Biofrontera, I'm medical Chief
as flagship product skin AKs we Our are to to call can skin sometimes Actin the caused exposure or keratosis lesions keratosis of them, by are sunlight. which treatment that cancer. actinic excessive focuses lead on
for of antibiotics infection. topical market bacterial impetigo, which treatment also We is a skin
sales to me Before strategy product the and and XXXX. nine expenses higher an is of third the QX XX, from of sales reflecting operating volume for of introduce was were $XX months you financial you million XX.X% due increase increased a and a price. a $X.X net about to September improved total million company and to million negative average negative XX, general or administrative increased million XX.X%. $XX.XX XX, financial expense. In million. $XX.X headcount. million. settlement million, million XXXX. to and higher lesser XXXX $X.X for revenue September the three equivalents cash our XX, three negative XXXX three extent XX% was selling, This were $XX.X XXXX extent marketing versus Adjusted an selling to Adjusted from increased expense months the The the primarily September for lesser were $X.X Total and legal the let of million during to XXXX increased XXXX update, a year. ago. campaign one the telling ended with due And revenues September EBIDA increase million of $X.X for EBIDA more Ameluz. for months $X million of expenses negative primarily revenue ended $X.X to $X.X administrative period the due and and results Net our Selling, million of compared products, year. first general as last ended third $X.X our was Cost and loss of our quarter due quarter months loss increases third the year higher quarter, our Cash same primarily Ameluz, margin to
proceeds the million to the that provided proceeds of we investment another the into gross $XX IPO. from As close, we of company, mentioned, $XX following company. the quarter yesterday, has Furthermore, gross private our raised million published
through warrants, settled provide the company. also have which We to in another funds today, outstanding will $X.X million
potential As activities least a available next financing be But XX that and growth through opportunistic the funds the months. regards activities. support in to stage provide company, to we at today investing, sufficient financing capital believe we intend operating, to
sales Now even primarily our XX, year-to-date was increase financial partially of lower increase of million and moving It’s for on the the same sales to of $XX.X XXXX. Xepi. The to total our months in were offset ended time revenues product or September and million results, due for $XX.X Ameluz by XX%. higher XXXX nine million $X.X an
recommendation of XXXX. from of treatment for Total parts. that In-patients the million And sales to fact disclosures. in COVID-XX care sales. mid-March this product strong later remaining half in-office the XXXX, Dermatology recovering in albeit treatments to undergo expenses the million the business $XX.X furloughs, our we of revenue same the negligible we by showed salary voluntary In of and with pandemic. on XXXX, XXXX. hiring offices seasonality numbers slow our Senior reductions second we by rates product spend of After summer XX% American of the a Doctors' In nine for the starting multiple at from mitigate operating operating diagnosis increase ended a XXXX, stabilization Our lease in in observed that of mandatory patients willingness significant were The rising cash directly line of in to reopened of in point first XXXX; of the AK. affected temporary seasonally measures, in months April was in from sales year-to-date pandemic Biofrontera the for of From months revenue reduced by resulting is quarter freezing in remote usual quarter. headcount saw and served decline expenses and recovery increasing Leadership. through September indicates section XXXX to XXXX. and COVID-XX, including and XX, to the in increase the during signs global reductions, widespread Academy led risks and had official the $XX.X for fourth
delayed of product U.S. During sales the Xepi relaunch to pandemic, the targeted strategy and improve positioning. we our Ameluz focused on
licensed XXXX. our EBITDA for nine campaigns marketing during legal in earlier, as XXXX settlement various for launched hiring, And resumed million and ended million and XXXX have $X.X Adjusted have a we we respectively. months addition, million XXXX, third incurred the September During the in quarter a $X.X of negative negative $XX.XX products. XX, expense was mentioned
expansion, Accordingly, XX, I management during from include and operating long-term the more same $XX.X the XXXX improved respectively. with margin cost frequently balanced PDT issued EBIDA a September consistent million news expansion. XXXX refer operating loss technology, focused adjusted including XX.X% resource a for nine non-GAAP to and are a XX% periods. using market in objectives ended today of to traditional financial lamp we we earlier and effective improved reconciliation measures. financial utilization, because The Net winter. overhead negative Our to rapid table negative the a and the GAAP are leverage, revenue months information you during for $XX.X was the release million treatments on performed growth efficiencies, margin
first been and revenue second than and subject higher to quarters and some has third during fourth quarters. Our is the the during seasonality historically
form out that we our see the pandemic. we that We're in pleased has strong growth our are continue as have strategy uniquely with also our positioned commercial that, that Biofrontera dermatological company. quarter. pleased Given And normalized expect align treatment strategy. a focused leadership efforts marketing and maintain the that COVID-XX for momentum goals sales Overall to And revenue briefly development expenses commercial of to transitioning we of conditions. third the and in strengthen illustrate I'll the growth a
that with Biofrontera $X.X we November placement our leading gross million. flexibility our from position outstanding with public the of offering. Xnd, through proceeds The $XX warrants as we Hermann will million cash initial on and an As completed exercise along company. million proceeds announced mentioned strength the dermatology a and IPO yesterday in today private advance proceeds the $XX commercial
scalp licensed Our principal of combination and in positioning Ameluz in with sales grow United and our objective Three PDT growing of of product the treatment infrastructure. key First, our sales the following: BF-RhodoLED product and strategy as include sales the elements the in on by to to leading Ameluz expanding products the our principal is States. the our AK face for marketing
market potential Second, that pipeline And of product. licensed our existing expanding leveraging products for approvals of future of sales agreements. for and improving treatment label positioning our license our by the extensions through third, of the impetigo
market our strengthening of and medical strategies, KOL strategy based the a products and becoming communities robust territories data action, awareness driven our expansion and data affairs partner medical publication, scientific trusted through dynamic intend support. bolstering medical sales through optimize infrastructure. on in industry through to a sales Our of We our and is salesforce recognition, more commercial
our unlicensed me with you Ameluz. starting to let introduce Now, products,
call therapy our or for use with combination Ameluz. approved is PDT mentioned, it. is principal photodynamic we BF-RhodoLED Prescription our product in as drug lamp As
the cell the on on appear untreated as carcinoma, directed potentially the AK that develop potentially mild-to-moderate keratosis may lesion the face are of such lesions areas, bald, back into field For treatment piece superficial size called scale. of and hands. as sun severity precancerous typically life-threatening lesion arms Keratosis of face, and chronic the exposure squamous of a so skin left scalp, exposed skin directed cancers
the performed a common you're XX.X those should AK are hyperpigmented with PDT and followed drugs X% share cryotherapy States Cancer of AKs most million could remains Topical a disclaimer had in actinic treatments often treatment if treatment significant about of treatment XX% treatment for compared that AK, AKs market keratosis the develop in poses Skin people cell elevated, to spots rough and XXXX, million approximate with XX%. a a XXXX X% actinic United option If compared AKs were year. cryotherapy of an affects in disadvantages dominance, estimated Foundation, to texture. the XX The keratosis. market. According flaky, for for every treatments up market of as untreated its as share carcinoma In lesions an for Despite therapy. a left by PDT approximately as share a sorry, of market option the to
target to the focus a in We a cryotherapy, see particularly market share as further our which with pressure As for is our PDT opportunity patients opposed treatment such efforts. single more is than key as cryotherapy with Ameluz. towards XX attractive field directed the strategically We as commercial a in the AK believe to therapy, to opportunity guideline market such lesions. treatment lesion may of as cells there also help expand therapy,
that And prescription ages as of bacterial in adults of five, contagious use can on Topical impetigo, often was people strains, affected. be licensed get is two FDA mucosa. that more children caused Currently and Xepi. antibiotic by the It treatment months two and and covers specifically and most than age in been skin and red for any legs. arms drug most product Anyone a infection. sores second appear skin by approved FDA older. has highly is frequently once. Our Impetigo can a antibiotic common pupil face, can neck, children impetigo resistance bacteria. the to occurs the contract such known, the and Impetigo is causes it label infection no the against the resistant
And potential are in is months, year. in impetigo insurance million XXXX, with Xepi the believe there covered Although Xepi. during of written three it a one pharmacies of United every pre-approval about often market In without year-round through most of and are would be than for were by be States XX% than commercial that weather disease, covered is that requirements. more coming warmer indications occurs with generally and is can is most XX impetigo distributed commercial – the more prescriptions likely our years. drugs million for cases the similar specialty payers patients key advantages effective. or is Xepi there We considerable
an studies. update our ongoing on on Moving clinical to
and inflammatory physicians efficacy primary be as by our The endpoint in of two by to tubes between enroll as acne more favorable Our eight clinical study for durations well placebo. of study the announced is X Ameluz. safety development in sites options. financed with or Ameluz recently PDT three the patients, as Ameluz Ameluz include the is study in adults acne The site simultaneous addressable expanding Group hours the evaluating positioning will value improvement and with will will adults for the treated our and These complement indirectly studies. The agreement companies. of Ameluz of more to the are is one Biofrontera market Ameluz program placebo. designed offering license us number the study. existing a We by PDT with supply for of and with incubation moderate-to-severe Phase performed tested lesions commercial seven PDT the for Phase with product by clinical change to compared Xb our of initiations total application of the and providing XXX treatment strategy broadening sites with who moderate-to-severe assessed of symptoms acne PDT X the treatment by be conducting market Studies
study in XL will study second AK and tubes a study treatment of Ameluz three each field evaluate enroll The of located maximum together of AKs the larger study the content with XXXX. PDT new face That the completed patient RhodoLED patients safety in receive mild-to-severe will XXX directed tolerability will and our the scalp with treatment. early This lamp. on with of follows pharmacokinetic for Ameluz usage
three limits the effects the underway. on to treatment. product and have per in allowing before requested both were transient of focused positioning be meeting Currently per tubes of announced expanding the the the changed market information tube of FDA. focusing Ameluz to use study treatment. share market that site initiations Ameluz safety the product Both information with the for sites FDA studies to on we are June, one and commenced to In application optimizing study studies amendment the PK another As results presented
recruitment of the patient expect the to We begin end before year.
States Ameluz ongoing forward have And combination these We for that, in evaluate I we the study concluding. carcinoma. superficial addition, updates. with in taking who basal to United look our in In our with of conference you X treatment to would the cell I to Phase call. shareholders to the to like an conclude business now PDT to this and all to Thank time like to line participate are the would questions. open studies
